Search Result

Results for "

BRCA

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (9) Cathepsin (1) CDK (1) Deubiquitinase (1) DNA/RNA Synthesis (6) Histone Methyltransferase (1) NEKs (1) PARP (13) PROTACs (2) Proteasome (1) RAD51 (5) Reactive Oxygen Species (1) Small Interfering RNA (siRNA) (2) VEGFR (1)
By Research Areas:	Cancer (30)
Oligonucleotides:	Pre-designed siRNA Sets (2) siRNAs (2)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Recombinant Proteins

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-100862

BRCA1-IN-2 2 Publications Verification	PARP	Cancer
BRCA1-IN-2 (compound 15) is a cell-permeable protein-protein interaction (PPI) inhibitor for *BRCA1* with an IC₅₀ of 0.31 μM and a K_d of 0.3 μM, which shows antitumor activities via the disruption of BRCA1 (BRCT)₂/protein interactions .

HY-162859

AB25583	Others	Cancer
AB25583 is a Polθ helicase (Polθ-hel) small molecule inhibitor, with an IC₅₀ value of 6 nM. AB25583 selectively kills BRCA1/2 deficient cells and works in synergy with Olaparib (HY-10162) in cancer cells carrying pathogenic BRCA1/2 mutations. AB25583 can be used for tumor research .

HY-160700

TNG348	Deubiquitinase	Cancer
TNG348 is an orally active ubiquitin-specific protease USP1 inhibitor that can be used in research on cancers with BRCA1/2 mutations or HRD+ (Homologous Recombination Deficiency positive) status .

HY-126020

Bractoppin 2 Publications Verification	DNA/RNA Synthesis RAD51	Cancer
Bractoppin is a potent and selective agent-like inhibitor of phosphopeptide recognition by the *human BRCA1 tandem(t) BRCT domain* (binding IC₅₀: 74 nM). Bractoppin diminishes BRCA1 recruitment to DNA breaks, in turn suppressing damage-induced G2 arrest and assembly of the recombinase, RAD51. Bractoppin preferentially inhibits BRCA1 tBRCT-dependent steps in the DNA damage response .

HY-100863

BRCA1-IN-1	PARP	Cancer
BRCA1-IN-1 is a novel small-molecule-like *BRCA1* inhibitor with IC₅₀ and K_i of 0.53 μM and 0.71 μM, respecrively.

HY-162104

BRCA2-RAD51-IN-1	Others	Cancer
BRCA2-RAD51-IN-1 (Compound 46) is a *BRCA2-RAD51* inhibitor with an EC₅₀ value of 28 μM. BRCA2-RAD51-IN-1 has antitumor activity .

HY-RS01593

BRCA1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
BRCA1 Human Pre-designed siRNA Set A contains three designed siRNAs for BRCA1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

BRCA1 Human Pre-designed siRNA Set A BRCA1 Human Pre-designed siRNA Set A

HY-RS01594

BRCA2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
BRCA2 Human Pre-designed siRNA Set A contains three designed siRNAs for BRCA2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

BRCA2 Human Pre-designed siRNA Set A BRCA2 Human Pre-designed siRNA Set A

HY-P990873

*Anti-BRCA1 Antibody (BR64)*	DNA/RNA Synthesis	Others
Anti-BRCA1 Antibody (BR64) is a kind of mouse IgG1, κ chimeric antibody, targeting to human *BRCA1. The recommend isotype control of Anti-BRCA*1 Antibody (BR64): Mouse IgG1 kappa, Isotype Control (HY-P99977).

HY-150765

PARP1-IN-12	PARP Apoptosis	Cancer
PARP1-IN-12 is a potent PARP1 inhibitor with an IC₅₀ of 2.99 nM. PARP1-IN-12 exhibits antiproliferative activity, can induce cell apoptosis and cause cycle arrest at G2/M phase. PARP1-IN-12 also can induce DNA double strand breaks (DSBs) in *BRCA*-deficient cells .

HY-148183

Homologous recombination-IN-1	RAD51	Cancer
Homologous recombination-IN-1 is a novel RAD51-BRCA2 protein-protein interaction inhibitor (EC₅₀=19 μM). Homologous recombination-IN-1 can interfere with homologous recombination .

HY-150958

RAD51-IN-8	RAD51	Cancer
RAD51-IN-8, a new RAD51 binder, is a *RAD51-BRCA2* inhibitor that inhibits the RAD51 BRCA2 protein protein interaction. RAD51-IN-8 also is a protein−protein interaction (PPI) inhibitor. RAD51-IN-8 has inhibitory activity for H4A4 with an EC₅₀ value of 19 μM .

HY-139156

SK-575	PROTACs PARP	Cancer
SK-575 is a highly potent and specific proteolysis-targeting chimera (PROTAC) degrader of PARP1, with an IC₅₀ of 2.30 nM. SK-575 potently inhibits the growth of cancer cells bearing BRCA1/2 mutations .

HY-124691

D-I03 2 Publications Verification	DNA/RNA Synthesis	Cancer
D-I03 is a selective RAD52 inhibitor with a K_d of 25.8 µM. D-I03 specifically inhibits RAD52-dependent single-strand annealing (SSA) and D-loop formation with IC₅₀s of 5 µM and 8 µM, respectively. D-I03 suppresses growth of BRCA1- and BRCA2-deficient cells and inhibits formation of damage-induced RAD52 foci, but does not effect on RAD51 foci induced by Cisplatin .

HY-168094

PARP1-IN-30	PARP	Cancer
PARP1-IN-30 (Compound 3) is a specific and potent PARP1 inhibitor with cytotoxicity. PARP1-IN-30 allows precise inhibition of PARP1 in tumor cells with breast cancer 1 protein (BRCA1) or BRCA2 deficiencies. PARP1-IN-30 is promising for research of cancers .

HY-155766

PARP1-IN-14	PARP Apoptosis	Cancer
PARP1-IN-14 (compound 19k) is a potent PARP1 inhibitor, with an IC₅₀ of 0.6 ± 0.1 nM. PARP1-IN-14 exhibits antiproliferative effect against both MDA-MB-436 (BRCA1 ^−/−) and Capan-1 (BRCA2 ^−/−) cells with IC₅₀ values below 0.3 nM .

HY-161431

RTx-152	DNA/RNA Synthesis	Cancer
RTx-152 traps Polθ on DNA and is an allosteric Polθ-pol inhibitor (IC₅₀: 6.2 nM). RTx-152 selectively kills HR-deficient cancer cells, and suppresses PARP inhibitor resistance in multiple genetic backgrounds, including homologous recombination (HR)-proficient cells. RTx-152 selectively kills BRCA2-null cells .

HY-W327122

BAP1-IN-1	Others	Cancer
BAP1-IN-1 (Compound 8) is a BRCA1 associated protein 1 (BAP1) catalytic activity inhibitor with an IC₅₀ of 0.1-1 μM .

HY-114778

Fluzoparib 1 Publications Verification SHR3162; Fuzuloparib	PARP	Cancer
Fluzoparib (SHR3162) is a potent and orally active PARP1 inhibitor (IC₅₀=1.46±0.72 nM, a cell-free enzymatic assay) with superior antitumor activity. Fluzoparib selectively inhibits the proliferation of homologous recombination repair (HR)-deficient cells, and sensitizes both HR-deficient and HR-proficient cells to cytotoxic agents. Fluzoparib exhibits good pharmacokinetic properties in vivo and can be used for BRCA1/2-mutant relapsed ovarian cancer research .

HY-120750

A 62176 hydrochloride	Others	Cancer
A 62176 hydrochloride is a compound that targets DNA topoisomerase II and has the activity of inhibiting purine synthesis in cancer cells. A 62176 hydrochloride interferes with c-MYC mRNA expression by interacting with G-quadruplex. The main mechanism of action of A 62176 hydrochloride is by displacing nucleosomes from the quadruplex of non-template strand rDNA, resulting in rapid redistribution of nucleosomes. The application potential of A 62176 hydrochloride is that it causes DNA damage and relies on BRCA1/2-mediated homologous recombination and DNA-PK-mediated non-homologous end-joining pathways to repair the damage .

HY-132885

PARP/EZH2-IN-1	PARP Histone Methyltransferase	Cancer
PARP/EZH2-IN-1 is a first-in-class dual PARP (IC₅₀ 6.87 nM) and EZH2 (IC₅₀ 36.51 nM) inhibitor for triple-negative breast cancer with wild-type BRCA.

HY-P10516

BRC4 peptide	DNA/RNA Synthesis RAD51	Cancer
BRC4 peptide is a specific peptide in BRCA2 protein that interacts with RAD51 protein to help repair broken DNA chains. BRC4 peptide can be used to study DNA repair mechanisms and cancer occurrence .

HY-162706

BSJ-5-63	PROTACs CDK	Cancer
BSJ-5-63 is a potent CDK12, CDK7, CDK9 PROTAC degrader. BSJ-5-63 BSJ-5-63 decreases the protein expression of CDK12, CDK7, CDK9, RNAPII, Cyclin K. BSJ-5-63 decreases the mRNA expression of BRCA1, BRCA2. BSJ-5-63 shows anticancer activity and has the potential for the research of prostate cancer (Pink: ligand for target protein (HY-150948); black: linker (HY-W140827); Blue: E3 ligase ligand (HY-112078)) .

HY-162477

TS-24	Cathepsin Apoptosis	Cancer
TS-24 is an inhibitor for cathepsin S, with an IC₅₀ of 4.3 μM. TS-24 exhibits radiosensitizing activity in wild type breast cancer susceptibility gene 1 (BRCA1) and in TNBC xenograft mice model, through induction of apoptosis .

HY-150147

CAM833	RAD51 Apoptosis	Cancer
CAM833 is a potent orthosteric inhibitor of the interaction between *BRCA2* and RAD51 with a K_d of 366 nM against the ChimRAD51 protein. CAM833 also inhibits RAD51 oligomerization. CAM833 increases the progression of G2/M-arrested cells into apoptosis .

HY-157212

PARP-1/Proteasome-IN-1	Apoptosis PARP Proteasome	Cancer
PARP-1/Proteasome-IN-1 (compound 42i) is a dual PARP-1 and proteasome inhibitor with significant inhibitory effects on breast cancer. PARP-1/Proteasome-IN-1 can downregulate the expression of BRCA1 and RAD51 to inhibit homologous recombination repair function and induce apoptosis .

HY-125010

Dicycloplatin	DNA/RNA Synthesis Apoptosis	Cancer
Dicycloplatin is a DNA damage inducer. Dicycloplatin induces DNA damage by activating biphosphorylated checkpoint kinase 2 (CHK2), breast cancer 1 (BRCA1) and triphosphorylated p53. Dicycloplatin can induce cell cycle arrest, inhibit proliferation and lead to apoptosis in prostate cancer PC3 cells and lung cancer NCI/H446 cells. Dicycloplatin can be used in cancer researchr .

HY-122639

ZINC05007751 1 Publications Verification	NEKs	Cancer
ZINC05007751 is a potent NIMA-related kinase NEK6 inhibitor with an IC₅₀ of 3.4 μM. ZINC05007751 shows antiproliferative activity against a panel of human cancer cell lines, and displays a synergistic effect with Cisplatin and Paclitaxel in a BRCA2 mutated ovarian cancer cell line. ZINC05007751 is very selective against NEK1 and NEK6 with no significant activity was observed against NEK2, NEK7, and NEK9 .

HY-155246

PARP1-IN-15	Apoptosis PARP	Cancer
PARP1-IN-15 (Compound 6) is a PARP1 inhibitor. PARP1-IN-15 inhibits tankyrase (TNKS) and facilitates DNA double-strand breaks damage. PARP1-IN-15 induces tumor cell apoptosis. PARP1-IN-15 has anti-cancer activity in triple-negative breast cancer (TNBC) cells and TNBC patient-derived organoids. PARP1-IN-15 can be used for research of TNBC with or without BRCA1 mutations .

HY-155965

VEGFR/PARP-IN-1	VEGFR PARP Apoptosis	Cancer
VEGFR/PARP-IN-1 (Compound 14b) is a VEGFR/PARP dual inhibitor (IC₅₀s: 191 nM and 60.9 nM respectively). VEGFR/PARP-IN-1 inhibits DNA damage repair, induces cell apoptosis, and arrests cell in the G2/M phase. VEGFR/PARP-IN-1 has good antiproliferative efficacy against BRCA wild-type breast cancer cells (IC₅₀: 4.1 and 3.5 μM for MDA-MB-231 and MCF-7 cells). VEGFR/PARP-IN-1 is an antitumor and anti-metastasis agent .

HY-161934

PARP1-IN-27	PARP Reactive Oxygen Species Apoptosis	Cancer
PARP1-IN-27 (Compound 9B) is the inhibitor for PARP1 and PARP2, with IC₅₀ of 2.53 nM and 6.45 nM in cell SUM149PT. PARP1-IN-27 inhibits the proliferation of BRCA-mutated cancer cells SUM149PT, HCC1937 and Capan-1, with IC₅₀ of 0.62, 1.91 and 4.26 μM respectively. PARP1-IN-27 aggravates DNA double-strand breaks, increases ROS generation, arrests cell cycle at G2/M phase, and induces apoptosis in SUM149PT .

HY-168722

PROTAC PARP1 degrader-3	PARP	Cancer
PROTAC PARP1 degrader-3 (Compound C6) is a degrader for PARP1 with a DC₅₀ of 58.14 nM. PROTAC PARP1 degrader-3 exhibits cytotoxicity in cancer cell SW-620 and LOVO with IC₅₀ of 1.63 μM and 2.84 μM. PROTAC PARP1 degrader-3 exhibits a synergistic effect with SN-38 (HY-13704) in BRCA-mutated colon cancer cell with a combination index (CI) of 0.487. (Blue: Ligand for E3 ligase Cereblon (HY-23095); Pink: Ligand for target protein (HY-10619); Black: Linker (HY-16872))

Cat. No.	Product Name

HY-L077

Anti-Pancreatic Cancer Compound Library	3,012 compounds
Pancreatic cancer is a devastating disease with a low overall survival rate. Chemotherapy is the most common treatment for patients presenting with advanced pancreatic cancer. More recently, the era of targeted therapies has generated a lot of interest in discovering better approaches for patients with pancreatic cancer. Commonly mutated genes in pancreatic cancer include K-ras (in 74-100% of cases), p16INK4a (up to 98%), p53 (43 to 76%), DPC4 (about 50%), HER-2/neu (in about 65%) and FHIT (found in 70% of cases). Other genes involved are notch1, Akt-2, BRCA2 and COX-2. These proteins are important targets of target therapies for pancreatic cancer. MCE offers a unique collection of 3,012 compounds with identified and potential anti- pancreatic cancer activity. These compounds target K-Ras, p53, HER2, Notch, AKT, etc. MCE anti-pancreatic cancer compound library is a useful tool for anti-pancreatic cancer drugs screening and other related research.

Anti-Pancreatic Cancer Compound Library

3,012 compounds

Pancreatic cancer is a devastating disease with a low overall survival rate. Chemotherapy is the most common treatment for patients presenting with advanced pancreatic cancer. More recently, the era of targeted therapies has generated a lot of interest in discovering better approaches for patients with pancreatic cancer. Commonly mutated genes in pancreatic cancer include K-ras (in 74-100% of cases), p16INK4a (up to 98%), p53 (43 to 76%), DPC4 (about 50%), HER-2/neu (in about 65%) and FHIT (found in 70% of cases). Other genes involved are notch1, Akt-2, BRCA2 and COX-2. These proteins are important targets of target therapies for pancreatic cancer.

MCE offers a unique collection of 3,012 compounds with identified and potential anti- pancreatic cancer activity. These compounds target K-Ras, p53, HER2, Notch, AKT, etc. MCE anti-pancreatic cancer compound library is a useful tool for anti-pancreatic cancer drugs screening and other related research.

Cat. No.	Product Name	Target	Research Area

HY-P10434

BRC4wt BRC4 repeat motif	Peptides	Cancer
BRC4wt (BRC4 repeat motif) is part of the BRACA2 tumor suppressor protein, which exhibits inhibitory activity against interaction of the BRACA2 protein with RAD51, and is involved in the repair of DNA damage .

HY-P10516

BRC4 peptide	DNA/RNA Synthesis RAD51	Cancer
BRC4 peptide is a specific peptide in BRCA2 protein that interacts with RAD51 protein to help repair broken DNA chains. BRC4 peptide can be used to study DNA repair mechanisms and cancer occurrence .

Cat. No.	Product Name	Target	Research Area

HY-P990873

*Anti-BRCA1 Antibody (BR64)*	DNA/RNA Synthesis	Others
Anti-BRCA1 Antibody (BR64) is a kind of mouse IgG1, κ chimeric antibody, targeting to human *BRCA1. The recommend isotype control of Anti-BRCA*1 Antibody (BR64): Mouse IgG1 kappa, Isotype Control (HY-P99977).

Species:	Human (8)
Tag:	His (4) SUMO (1) Tag Free (4) Strep (1) GST (1) Flag (1)
Source:	HEK293 (1) Sf9 insect cells (2) E. coli (5)

Cat. No.	Compare	Product Name	Species	Source

HY-P72107

	BRCC36 Protein, Human (His-SUMO) BRCA1-A complex subunit BRCC36; BRCA1/BRCA2 containing complex subunit 3; BRCA1/BRCA2 containing complex subunit 36; BRCA1/BRCA2-containing complex subunit 3; BRCA1/BRCA2-containing complex subunit 36; Brcc3; BRCC3_HUMAN; BRCC36; BRISC complex subunit BRCC36; C6.1A ; Chromosome X open reading frame 53; CXorf53; Lys-63-specific deubiquitinase BRCC36; OTTHUMP00000061450	Human	E. coli
	BRCC36 is a metalloprotease that selectively cleaves "Lys-63" linked polyubiquitin chains, especially histones H2A and H2AX in the BRCA1-A complex during the DNA damage response. As the catalytic subunit of the BRISC complex, it also targets “Lys-63”-linked ubiquitin in various substrates, affecting mitotic spindle assembly and interferon signaling. BRCC36 Protein, Human (His-SUMO) is the recombinant human-derived BRCC36 protein, expressed by E. coli , with N-6*His, N-SUMO labeled tag. The total length of BRCC36 Protein, Human (His-SUMO) is 315 a.a., with molecular weight of ~51.9 kDa.

HY-P703091

	BRCA1 Protein, Human RNF53	Human	E. coli
	BRCA1 Protein, Human is the recombinant human-derived BRCA1, expressed by E. coli , with tag Free labeled tag. The total length of BRCA1 Protein, Human is 214 a.a.,

HY-P703092

	BRCA2 Protein, Human (HEK293, His, Strep, Flag) FACD; FANCD1	Human	HEK293
	BRCA2 Protein, Human (HEK293, His, Strep, Flag) is the recombinant human-derived BRCA2, expressed by HEK293 , with Strep, His, Flag labeled tag. The total length of BRCA2 Protein, Human (HEK293, His, Strep, Flag) is 715 a.a.,

HY-P76746

	BCCIP Protein, Human (sf9) BRCA2 and CDKN1A-interacting protein; P21- and CDK-associated protein 1; TOK1	Human	Sf9 insect cells
	BCCIP proteins contribute to interphase microtubule organization and anchoring as well as spindle pole organization and stability during mitosis. BCCIP protein may induce cell cycle arrest by enhancing CDK2 inhibition and participate in DNA damage repair through homologous recombination with BRCA2. BCCIP Protein, Human (sf9) is the recombinant human-derived BCCIP protein, expressed by Sf9 insect cells , with tag free.

HY-P701462

	BAP1 Protein, Human BAP1; Ubiquitin carboxyl-terminal hydrolase BAP1; BRCA1-associated protein 1; Cerebral protein 6	Human	E. coli
	BAP1 protein deubiquitinates histone H2A and HCFC1, mediating deubiquitination of H2AK119ub1. It regulates cell growth by deubiquitinating HCFC1 chains and inhibits BRCA1 and BARD1 activity. BAP1 also protects itself from cytoplasmic sequestration and acts as a tumor suppressor. BAP1 Protein, Human is the recombinant human-derived BAP1 protein, expressed by E. coli , with tag free. The total length of BAP1 Protein, Human is 728 a.a., .

HY-P701463

	BAP1 Protein, Human (His) BAP1; Ubiquitin carboxyl-terminal hydrolase BAP1; BRCA1-associated protein 1; Cerebral protein 6	Human	E. coli
	BAP1 protein deubiquitinates histone H2A and HCFC1, mediating deubiquitination of H2AK119ub1. It regulates cell growth by deubiquitinating HCFC1 chains and inhibits BRCA1 and BARD1 activity. BAP1 also protects itself from cytoplasmic sequestration and acts as a tumor suppressor. BAP1 Protein, Human (His) is the recombinant human-derived BAP1 protein, expressed by E. coli , with N-6*His labeled tag. The total length of BAP1 Protein, Human (His) is 728 a.a., .

HY-P76747

	BCCIP Protein, Human (sf9, His-GST) BRCA2 and CDKN1A-interacting protein; P21- and CDK-associated protein 1; TOK1	Human	Sf9 insect cells
	BCCIP proteins contribute to interphase microtubule organization and anchoring as well as spindle pole organization and stability during mitosis. BCCIP protein may induce cell cycle arrest by enhancing CDK2 inhibition and participate in DNA damage repair through homologous recombination with BRCA2. BCCIP Protein, Human (sf9, His-GST) is the recombinant human-derived BCCIP protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.

HY-P701535

	BRAP Protein, Human BRAP; BRCA1-associated protein; BRAP2; Impedes mitogenic signal propagation; IMP; RING finger protein 52; RING-type E3 ubiquitin transferase BRAP2; Renal carcinoma antigen NY-REN-63	Human	E. coli
	BRAP protein acts as a negative regulator of MAP kinase activation, inhibits the formation of the Raf/MEK complex, and may inactivate the KSR1 scaffolding protein. As a Ras-responsive E3 ubiquitin ligase, BRAP undergoes autopolyubiquitination upon Ras activation, releasing its inhibitory effect on Raf/MEK complex formation. BRAP Protein, Human is the recombinant human-derived BRAP protein, expressed by E. coli , with tag free. The total length of BRAP Protein, Human is 591 a.a., .

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80489

	BRCA1 Antibody (YA819)	IHC-P	Human, Mouse
	BRCA1 Antibody (YA819) is a non-conjugated and Mouse origined monoclonal antibody about 208 kDa, targeting to BRCA1. It can be used for IHC-P assays with tag free, in the background of Human, Mouse.

HY-P80573

	BRCA1 Antibody BRCA1; RNF53; Breast cancer type 1 susceptibility protein; RING finger protein 53	WB, IHC-F, IHC-P, ICC/IF, ELISA	Human, Rat
	BRCA1 Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 208 kDa, targeting to BRCA1. It can be used for WB,IHC-F,IHC-P,ICC/IF,ELISA assays with tag free, in the background of Human, Rat.

HY-P82549

	BRAT1 Antibody (YA2294) BRCA1-associated ATM activator 1; BRCA1-associated protein required for ATM activation protein 1	WB, ICC/IF, IP	Human
	BRAT1 Antibody (YA2294) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA2294), targeting BRAT1, with a predicted molecular weight of 88 kDa (observed band size: 88 kDa). BRAT1 Antibody (YA2294) can be used for WB, ICC/IF, IP experiment in human background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: